Evaluation of a web-based intervention for improving HIV/AIDS knowledge in rural Yunnan, China. -
L Tian, S Tang, W Cao, K Zhang, V Li, R Detels - AIDS, 2007 - aidsonline.com
... Web-based intervention to improve HIV/AIDS knowledge Tian et ... 27.2 0.3 32.9 1.8 39.8
?3.1 0.78 0.50 0.29 An HIV-infected pregnant woman can transmit HIV to her ...
A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding -
CD Rizzuto, R Wyatt, N Hern?ndez-Ramos, Y Sun, PD … - Science, 1998 - sciencemag.org
... that you are using a browser that does not support current Web standards. ... Table 1.
Phenotypes of HIV-1 YU2 gp120 mutants ... 381 E/R (0.07), 0.07, 0.81, 0.75, 0.29, 0.96 ...
… drug susceptibility and response to initial therapy among recently HIV-infected subjects in North …
SJ Little, JP Routy, ES Daar, M Markowitz, AC … - New England Journal of Medicine, 2002 - gateway.nlm.nih.gov
... and ABI sequence analysis was used to evaluate the HIV pol region. ... to the nucleoside
reverse transcriptase inhibitors (NRTI) was observed (p = 0.29). ...
Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy -
DV Havlir, R Bassett, D Levitan, P Gilbert, P … - JAMA, 2001 - Am Med Assoc
... 95% CI, 0.29-1.72; P = .55, Fisher exact test). When the case definition of
intermittent viremia was changed to use a virologic threshold of HIV RNA greater ...
Hepatitis C and Progression of HIV Disease -
MS Sulkowski, RD Moore, SH Mehta, RE Chaisson, DL … - JAMA, 2002 - Am Med Assoc
... ultimately received HAART (RH, 1.09; 95% CI, 0.88-1.34) and in the subgroup of 250
patients with well-controlled HIV replication (RH, 0.57; 95% CI, 0.29-1.13). ...
Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3 -
AG Gharavi - Proceedings of the National Academy of Sciences, 2004 - National Acad Sciences
... ing information on the PNAS web site) and ... score) (0.34 cholesterol) (0.29 BUN) (0.29
proteinuria) (0.01 ... Concerning transgene status, HIV-1 transgene carriers ...
A Case Control Study of Osteonecrosis in HIV.
AN SCRIBNER, DJ SKIEST, D MARCANTONIO, F HAMID, PV … - Abstr Intersci Conf Antimicrob Agents Chemother Intersci …, 1999 - gateway.nlm.nih.gov
... were matched with 2 controls for HIV positivity and date of diagnosis.RESULTS: The
incidence of osteonecrosis in our HIV clinic population was 0.29% in 1998. ...
Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097)
C Katlama, S Dominguez, C Duvivier? - IN: Abstracts of the 10 thConference on Retroviruses and …, 2003 - gateway.nlm.nih.gov
... versus 62% at W12 and 50% at W24 in the Def.G (p = 0.007 and p = 0.043, respectively)
Median decrease in HIV RNA from baseline was -0.37 at W12, -0.29 at W24 ...
… and safety of stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects in …
R Pollard, D Peterson, D Hardy, L Pedneault, C … - 3rd Conference on Retroviruses and Opportunistic Infections - gateway.nlm.nih.gov
... 90 CD4 cells/mm3 at week 8. Changes in HIV RNA observed in individual subjects ranged
from 0.29 log (10) increase to 2.9 log (10) decrease at week 8. Follow-up ...
HAART exposure influences distribution and characteristics of HIV-associated neurologic disorders: …
A Ammassari, P Cinque, P Lorenzini, A Cingolani, … - Int Conf AIDS, 2002 - gateway.nlm.nih.gov
... Characteristics of CNS diagnoses, HIV and HAART histories are collected. ...
CD4>200+VL<500 significantly reduce probability of TE (0.45;0.29-0.69), HSV (0.29; ...
Source: Google Scholar |
